“Key unresolved issues” relating to the European Commission’s proposals on EU-level compulsory licensing must be addressed, such as whether companies may be forced to share trade secrets, say several industry groups, including EFPIA and MedTech Europe, which represent the European R&D-based pharmaceutical and medical devices industries respectively.
Amendments to the proposals adopted by the European Parliament in March included some changes that will be welcomed by industry, such as a requirement that voluntary licenses are sought ahead of compulsory licenses, a better approach to remuneration and greater involvement of the rights holder in the process. (Also see "EU Committee OKs More Pharma-Friendly Compulsory Licensing Plan" - Pink Sheet, 15 February, 2024
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?